Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease by Di Pardo, Alba et al.
O R I G I N A L A R T I C L E
Stimulation of S1PR5 with A-971432, a selective
agonist, preserves blood–brain barrier integrity and
exerts therapeutic effect in an animal model of
Huntington’s disease
Alba Di Pardo1, Salvatore Castaldo1, Enrico Amico1, Giuseppe Pepe1,
Federico Marracino1, Luca Capocci1, Alfredo Giovannelli1, Michele Madonna1,
Jeroen van Bergeijk2, Fabio Buttari1, Elizabeth van der Kam2 and
Vittorio Maglione1,*
1IRCCS Neuromed, Localita´ Camerelle, 86077, Pozzilli (IS), Italy and 2AbbVie Deutschland GmbH & Co KG,
Knollstrasse 50, 67061 Ludwigshafen, Germany
*To whom correspondence should be addressed at: Centre for Neurogenetics and Rare Diseases, IRCCS Neuromed, Pozzilli (IS) 86077, Italy.
Tel: þ39 0865915212; Fax: þ39 0865927575; Email: vittorio.maglione@neuromed.it
Abstract
Huntington’s disease (HD) is the most common neurodegenerative disorder for which no effective cure is yet available. Although
several agents have been identified to provide benefits so far, the number of therapeutic options remains limited with only
symptomatic treatment available. Over the past few years, we have demonstrated that sphingolipid-based approaches may open
the door to new and more targeted treatments for the disease. In this study, we investigated the therapeutic potential of stimulat-
ing sphingosine-1-phosphate (S1P) receptor 5 by the new selective agonist A-971432 (provided by AbbVie) in R6/2 mice, a widely
used HD animal model. Chronic administration of low-dose (0.1 mg/kg) A-971432 slowed down the progression of the disease and
significantly prolonged lifespan in symptomatic R6/2 mice. Such beneficial effects were associated with activation of pro-survival
pathways (BDNF, AKT and ERK) and with reduction of mutant huntingtin aggregation. A-971432 also protected blood–brain barrier
(BBB) homeostasis in the same mice. Interestingly, when administered early in the disease, before any overt symptoms, A-971432
completely protected HD mice from the classic progressive motor deficit and preserved BBB integrity. Beside representing a prom-
ising strategy to take into consideration for the development of alternative therapeutic options for HD, selective stimulation of S1P
receptor 5 may be also seen as an effective approach to target brain vasculature defects in the disease.
Introduction
Huntington’s disease (HD) is the most common rare brain
disorder characterized by progressive striatal and cortical de-
generation and associated motor, cognitive and behavioural
disturbances (1). The disease-causing mutation is a polyglut-
amine (polyQ) repeat expansion (>36 repeats) within huntingtin
(Htt), a ubiquitous protein whose functions are not yet
completely elucidated (2). Expansion of the polyQ stretch
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endows mutant Htt (mHtt) with toxic properties, and results in
the development of a broad array of cell dysfunctions in neuro-
nal and non-neuronal cell populations (2–4).
A number of evidence demonstrates that an aberrant sphin-
golipid homeostasis represents an additional pathological event
that may contribute to the pathogenesis of the disease (5–8). In
this context, defective expression of the enzymes involved in
the metabolism of sphingosine-1-phoshate (S1P) with the con-
sequent reduction in its levels, may represent a critical patho-
logical determinant in both experimental models and human
patients (7,9–12).
S1P is a potent signaling bioactive sphingolipid that acts in-
tracellularly as a second messenger and extracellularly in an
autocrine and paracrine fashion by activating five known G
protein-coupled receptors, S1PR1–5, which are ubiquitously
expressed throughout the body and in the central nervous sys-
tem (CNS) (13). Among all, S1PR5 is preferentially expressed in
oligodendrocytes, where it may regulate lipid content and mye-
lination (14) and in brain endothelial cells where it regulates
blood–brain barrier (BBB) tight junctions (15), whose function is
critical to paracellular transport and BBB permeability (16).
Impaired permeability of BBB has been described recently in
HD in both human tissues and animal models even at early
stages of the disease and it has been associated with reduced
expression of Claudin-5 and Occludin (17,18), two key structural
components of tight junction complex (16).
Defective brain vascular homeostasis may potentially be in-
cluded as additional neuropathological hallmark of the disease
and eventually identified as new a therapeutic target in the
future.
Modulators of S1P receptors are currently used to treat dif-
ferent brain-related disorders (19), including Rett Syndrome and
Amyotrophic Lateral Sclerosis (ALS) for which brain vasculature
defects have also been described (20). Non-selective stimulation
of S1P receptors by FTY720 (or Fingolimod), a FDA-approved
drug for the treatment of multiple sclerosis, is neuroprotective
and exerts disease-modifying effects also in multiple HD pre-
clinical models (21,22).
In this study, we investigated the potential therapeutic ben-
efits of a new selective brain penetrable S1PR5 agonist, A-971432
(AbbVie) (23) in a HD animal model and explored its potential
role in the maintenance of BBB integrity.
Treatment with 0.1 mg/kg (once daily) A-971432 blocked the
progression of the disease and prolonged lifespan in symptom-
atic R6/2 mice. Interestingly, the compound delayed the onset
of motor symptoms when administered early in the disease at
the pre-symptomatic stage.
The beneficial effects on motor deficit were associated
with activation of neuroprotective kinases AKT and ERK in
the striatum, elevation in the levels of cortical brain-derived
neurotrophic factor (BDNF) and with a significant amelioration
of neuropathology. Beside reducing mHtt aggregation, A-971432
exerted protective action on BBB homeostasis and preserved its
integrity.
Results
Chronic infusion of A-971432 prevents the worsening of
motor deficit in symptomatic R6/2 mice
Stimulation of S1P receptors, by the non-selective modulator
FTY720, has been previously reported to be beneficial in multiple
HD pre-clinical models (21,22). To assess any therapeutic poten-
tial of more targeted stimulation, selective activation of S1PR5
by A-971432 was investigated in symptomatic (7-week old)
R6/2 mice and in age-matched wild-type (WT) littermates.
Interestingly, chronic administration of A-971432 restored nor-
mal motor function in R6/2-treated mice within the first week of
treatment, and preserved them from the gradual motor deficit,
classically occurring during the disease, for the entire period of
the treatment (Fig. 1A and B).
Interestingly, improved motor skills in R6/2 mice were
associated with preserved body weight (Fig. 1C), whose loss is a
classical hallmark of the disease progression (21,24), and signifi-
cantly prolonged animal lifespan (Fig. 1D). No effects were ob-
served in WT mice (Fig. 1A and D) and no evidence of adverse
events were noted in none of the genotypes. In addition, phar-
macokinetic analysis of mouse serum samples revealed an ade-
quate exposure of A-971432 during the treatment comparable to
previous studies (23) (Supplementary Material, Table S1).
Administration of A-971432 leads to the activation of
neuroprotective pathways in the brain tissues from
symptomatic R6/2 mice
Our previous studies indicate that stimulation of multiple S1P
receptors exerts an overall neuroprotective action, evokes the
activation of prosurvival AKT and ERK cell signalling pathways
and increases the production of BDNF in vivo (21). Selective acti-
vation of S1PR5 is also reported to sustain cell survival by pro-
moting phosphorylation of AKT (14).
Here, we tested the possibility that A-971432, by selectively
stimulating S1PR5, might trigger the activation of similar pro-
survival pathways in HD animals.
To this purpose, 1 h after i.p. administration of the com-
pound, mice were sacrificed and brain tissues analyzed to as-
sess phosphorylation rate of AKT and ERK as well as expression
of BDNF. In line with our previous findings, administration of
A-971432 leaded to increased phosphorylation of the two kin-
ases (Fig. 2A and B) in the striatum of R6/2 mice and signifi-
cantly incremented the levels of BDNF in the cortex (Fig. 2C).
Administration of A-971432 ameliorated
neuropathology in symptomatic R6/2 mice
Next, with the aim of investigating any disease-modifying
properties of the compound, neuropathological studies were
carried out on brain tissues of R6/2 mice. First, the overall ef-
fect of A-971432 on the brain weight was evaluated. Chronic
administration of A-971432 prevented the classic brain weight
loss in R6/2 mice (Fig. 3A). Importantly, the compound had
the benefits of lowering also mHtt toxic aggregates; its
chronic administration was associated with reduced total
number of cells containing EM48-immunoreactive mHtt
aggregates as well as with decreased size of single aggregates
in the striatum of treated R6/2 mice with respect to untreated
controls (Fig. 3B–D). Reduction of mHtt aggregates after A-
971432 treatment was also confirmed by immunoblotting
analysis which showed a decrease of EM48-positive signal in
the stacking part of the gel (Fig. 3E and Supplementary
Material, Fig. S1).
Administration of A-971432-protected symptomatic
R6/2 mice from progressive BBB dysfunctions
Impairment of BBB permeability and reduced expression of the
tight junction proteins, Claudin-5 and Occludin, has been
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recently described in R6/2 mice (17,18). BBB homeostasis is a
quite complex condition and endothelial S1PR5 in the brain has
been reported to contribute to its integrity through regulation of
tight junction protein levels (15,23).
In the light of that, we explored the possibility that the selec-
tive targeting of S1PR5, by A-971432, might regulate BBB perme-
ability in symptomatic R6/2 mice, the only HD animal model
where altered BBB is clearly described (17,18). To this purpose,
at the end of the treatment, BBB leakage was assessed in symp-
tomatic R6/2 mice and age-matched WT littermates, through
the analysis of FITC-albumin extravasation into brain parenchy-
mal as described previously (18).
Interestingly, in line with our expectation, chronic infusion
of A-971432 attenuated the classic progressive BBB leakage and
therefore the FITC-albumin extravasation in striatal paren-
chyma (Fig. 4A and B).
Figure 2. A-971432 promotes the activation of pro-survival pathways in brain tissues from R6/2 mice. Representative cropped western blottings and densitometric
analysis of AKT (A) and ERK (B) phosphorylation levels in striatal tissues from vehicle- and A-971432-treated R6/2 mice at 11 weeks of age. Data are represented as
mean6SD. (HD, N¼5þ6). *, P<0.05; ***, P< 0.001 (unpaired t-test). Representative cropped western blottings and densitometric analysis of BDNF protein in cortical tis-
sues from the same mice (C). Data are represented as mean6SD. N¼5 for each group of mice. ***, P<0.001; ****, P< 0.0001 (one-way ANOVA with Tukey post-test).
Figure 1. Administration of A-971432 preserves motor function in R6/2 mice. Motor performance assessed by horizontal ladder task (WT, N¼6þ6; HD, N¼8þ8) (A)
and Rotarod (WT, N¼6þ6; HD, N¼8þ9) (B). Mouse body weight weekly measured during the entire period of the treatment (WT, N¼6þ6; HD, N¼8þ8) (C). Kaplan
Maier curve of survival (HD, N¼ 7þ7) (D). Arrows indicate when treatment started. Values are represented as mean6SD. @, P<0.05; @@, P<0.01 (vehicle-treated WT
vs. A971432-treated R6/2 mice). ££, P<0.01; £££, P<0.001 (A-971432-treated WT vs. A-971432-treated R6/2 mice). *, P<0.05; **, P<0.01; ***, P<0.001; ****, P< 0.0001 (vehi-
cle-treated R6/2 vs. A-971432-treated R6/2 mice). #, P<0.05; ##, P<0.01; ###, P<0.001; ####, P<0.0001 (vehicle-treated WT vs. vehicle-treated R6/2 mice). $, P<0.05; $$$,
P<0.001; $$$$, P<0.0001 (A-971432-treated WT vs. vehicle-treated R6/2 mice) (two-way ANOVA with Bonferroni post-test).
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Also, in order to further consolidate the association between
tight junction stability and BBB leakage, levels of Occludin and
Claudin-5 were examined in the treated mice. Immunoblotting
analysis showed that chronic infusion of A-971432 significantly
prevented the characteristic decrease in the expression of both
proteins (Fig. 4C). The effect of the compound on tight junction
proteins was also confirmed in WT mice (Supplementary
Material, Fig. S2).
Early infusion of A-971432 preserved BBB integrity and
delayed the onset of motor symptoms in R6/2 mice
We have recently demonstrated that first signs of BBB impair-
ment become evident early in the disease in R6/2 mice, even be-
fore overt motor symptoms appear (18). Here, we explored the
possibility that stimulation of S1PR5 might contribute to clarify
any potential link between impairment of BBB integrity and dis-
ease onset. Thus, the ability of A-971432 to influence the occur-
rence of disease symptoms and to impact on BBB homeostasis
was explored in mice that received the compound starting
from the pre-symptomatic (4-week old) stage of the disease (Figs
5 and 6). After 2 weeks of treatment, at the age of 6 weeks, when
motor deficit is classically fully detectable in R6/2 mice (Fig. 5), A-
971432 preserved normal motor function in treated mice with re-
spect to untreated controls. Interestingly, treatment prevented
the FITC-albumin extravasation, normally associated with this
stage of the disease (18) (Fig. 6A and B). From biochemical point
of view, maintained homeostasis of BBB after A-971432 was as-
sociated with normal levels of Occludin protein (Fig. 6C), but re-
duced levels of Claudin-5 (Fig. 6D).
Early administration of A-971432 suppresses
aggregation of mHtt in the CNS blood vessels
Evidence shows accumulation of mHtt aggregates in brain vas-
culature of symptomatic R6/2 mice and human HD post mortem
brains (17) and, the resulting compromise of the cerebral vascu-
lature is suggestive of BBB damage in the disease (17). Here,
Figure 3. Administration of A-971432 ameliorates neuropathology in R6/2 mice. Mouse brain weight (WT, N¼5þ5; HD, N¼6þ6) (A). **, P<0.01; ****, P<0.0001 (one-way
ANOVA with Tukey post-test). Representative micrograph (B), semi-quantitative analysis (C) of EM48-immunoreactive cells and aggregate area (D) in the striatum of
vehicle- and A971432-treated R6/2 mice at 11 weeks of age. Arrows indicate mHtt aggregates. Scale bar in represents 100 mm. Values are represented as mean6SD. WT,
N¼5þ5; HD, N¼6þ6. ****, P<0.0001 (unpaired t-test). (E) Immunoblotting showing EM48-positive mHtt aggregates and full-lenght Htt in striatal lysate from vehicle-
and A-971432-treated R6/2 mice at 11 weeks of age. The asterisk (*) on the representative EM48 immunoblotting indicates an un-specific band recognized by the
antibody.
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with the aim to investigate whether there exists a possible link
between BBB impairment and mHtt aggregation, we examined
mutant protein organization in the wall of carotid arteries,
normally considered a model for brain vasculature (25), from
A-971432-treated and untreated R6/2 mice. Interestingly, main-
tained BBB homeostasis in A-971432-treated HD mice was asso-
ciated with an attenuation of EM48-positive mHtt aggregate in
carotid vessels as qualitatively detected by histological analysis
(Fig. 7A). This result was quantitatively confirmed by immuno-
blottings that showed a significant decrease of SDS-insoluble
mHtt aggregates as detected by EM48 antibody in the stacking
part of the gels (Fig. 7B, C and D).
Discussion
Although numerous molecules have been screened for the devel-
opment of new treatments for HD, the identification of novel and
effective targets remains of great interest in HD. We and others
have largely contributed to the recognition of S1P metabolism as
new potential therapeutic target, and demonstrated that non-
selective modulation of S1P receptors may represent an effective
treatment in HD preclinical models (7,9,11,21,22,26).
In this study, we demonstrated for the first time, that
A-971432, a new selective S1PR5 agonist, is therapeutically effec-
tive in R6/2 mice, a widely used and well-characterized HD
Figure 4. Administration of A-971432 attenuates striatal BBB defects in symptomatic R6/2 mice. Representative fluorescence micrographs (A) and semi-quantitative
analysis (B) of FITC-albumin extravasation (bright green fluorescence) normalized on vessel marker laminin (red) in striatum of vehicle- and A-971432-treated R6/2
mice at 11 weeks of age and in age-matched WT controls. N¼5 for each group of mice. **, P<0.01; ***, P<0.001 (one-way ANOVA with Tukey post-test). CTVF, corrected
total vessel fluorescence. Scale bar in the merge monograph represents 100 mm. Representative cropped western blottings and densitometric analysis of Occludin
(C) and Claudin-5 (D) proteins in striatal tissues from the same mice. In each immunoblotting, all samples were run on the same gel. Non-adjacent samples were sepa-
rated by a black line. N¼5 for each group of mice. *, P< 0.05; **, P<0.01; ***, P< 0.001; ****, P<0.0001 (one-way ANOVA with Tukey post-test).
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animal model (27) which recapitulates many of the features of
human pathology (28–32). Chronic administration of A-971432
protected symptomatic R6/2 mice from progressive motor deficit,
normally associated with the disease course, and most impor-
tantly significantly delayed the onset of disease symptoms when
administered in pre-symptomatic stage in the same mice.
Treatment with A-971432 exerted beneficial effect on physi-
cal well-being of the disease mouse model; it preserved normal
body weight and significantly extended lifespan. From the
mechanistic point of view, it is still unknown the exact underly-
ing molecular mechanism, however, our findings revealed rele-
vant molecular and neuropathological changes. Stimulation of
S1PRs is generally associated with activation of cell signalling
cascade (33). Coherently, A-971432 leaded to the activation/
phosphorylation of pro-survival kinases AKT and ERK in brain
tissues from HD mice. This is particularly important in the con-
text of HD in which such kinase pathways are defective (34–36)
and whose stimulation results neuroprotective (5,37–39). Also,
A-971432-increased levels of the neurotrophin BDNF, whose sig-
nalling pathways have been reported to be aberrant in different
neurodegenerative disorders (40,41), including HD (42), and
whose restoration and/or enhanced bioavailability is widely de-
scribed to provide major support for striatal neurons (43) also in
R6/2 mice (44,45).
The molecular mechanisms by which A-971432 exerts bene-
ficial effects in HD remain to be further elucidated, however, our
results are coherent with other findings showing a correlation
between stimulation of S1P axis and activation of neuroprotec-
tive pathways in pre-clinical models of a number of brain disor-
ders, including HD (21,46,47).
Increased production of BDNF after A-971432 may likely rep-
resent the driving mechanism of neuroprotection in our study.
Hypothetically it can be either a direct result of S1PR5 stimula-
tion or an independent intracellular response, possibly related
to the activation of AKT and ERK pathways (41,48–50).
Preservation of normal motor function after A-971432 ad-
ministration in R6/2 mice well correlated with signs of neuro-
protection like prevented loss of brain weight and dramatic
reduction of EM48-positive mHtt aggregates in the striatum.
Although it is still debated whether aggregates are the toxic
mHtt species (51), interventions aimed at reducing their levels
are beneficial in different HD models (52).
A strong point of this study is the protective effect that
A-971432 has on BBB in vivo. In particular, attenuation of BBB
leakage, detectable through the FITC-albumin extravasation in
the brain parenchyma, is found after treatment either if started
at symptomatic or at pre-symptomatic stage of the disease.
From a molecular standpoint, this ‘functional’ result was
associated with an increased expression of the tight junction
proteins, Occludin and Claudin-5, that are directly involved in
regulating the integrity and proper functioning of the BBB
(53,54). Pharmacological elevation of both Claudin-5 and
Occludin levels increases trans-endothelial electrical resistance
and decreases endothelial permeability (55,56). Interestingly,
A-971432 has been reported to serve also as increaser of electri-
cal resistance in an in vitro model of BBB integrity (23).
The protective action that A-971432 exerts on the BBB is
likely attributable, at least in part, to the ability of the com-
pound to maintain the normal function of tight junction by reg-
ulating the levels of key proteins like Occludin and Claudin-5.
The effect of A-971432 administration on protein levels indi-
cates that the compound is able to either restore normal protein
setting in the tight junction organization or to partially prevent
the characteristic reduction the proteins Occludin and Claudin-
5 classically meet during the disease course (18).
The link between S1PR5 activation and change in the levels
of tight junction protein is still under investigation in HD, how-
ever, in vitro available evidence demonstrates that the down
regulation of the receptor leads to a reduction of Claudin-5 ex-
pression (15). Whether this is directly dependent on S1PR5 or
secondary to downstream activated pathways is not clear yet,
however, recent studies demonstrated that BDNF per se may
modulate expression of both Occludin and Claudin-5 proteins
in intestinal barrier (57,58).
Albeit A-971432 administered at the pre-symptomatic stage,
failed to preserve levels of Claudin 5, R6/2 mice remained pro-
tected from BBB leakage. Although not clear yet, these finding
suggest that the protective effect of A-971432 on BBB homeosta-
sis may likely contemplate the involvement of a plethora of
events ranging from functional to structural changes.
Indeed, beside other effects, A-971432 reduced the formation
of mHtt aggregates in carotid arteries, which, albeit do not rep-
resent the classical brain vessels, may likely mirror brain vascu-
lature response to the treatment.
How mHtt aggregates affect brain vascular system is not
clear yet and further studies are certainly needed, however, evi-
dence indicates that mHtt may affect endothelial architecture
or interfere with transcytosis and para-cellular transport (17).
mHtt aggregates have been detected inside multiple compo-
nents of the neurovascular unit like endothelial cells and peri-
cytes (17) for which, S1P receptors, including S1PR5, contribute
to proper functioning (15,59). In light of that, it is conceivable
that reduction of mHtt aggregates, in vascular unit, may amelio-
rate vascular function and ultimately contribute to the BBB
homeostasis.
To our best knowledge, this is the first and only evidence
demonstrating that stimulation of S1PRs is critical for the struc-
tural and functional preservation of BBB in HD, whose impair-
ment is becoming increasingly implicated in the pathogenesis
Figure 5. A-971432 delays the onset of motor deficit when administered in R6/2
mice starting from the pre-symptomatic stage. Mouse motor performance
assessed by Horizontal Ladder Task (WT, N¼4; HD¼5þ6). Arrows indicate
when treatment started. ##, P < 0.01; ####, P<0.0001 (vehicle- treated WT vs. ve-
hicle-treated R6/2 mice); *, P<0.05; ***, P<0.001 (vehicle-treated R6/2 vs. A-
971432-treated R6/2 mice) (two-way ANOVA with Bonferroni post-test).
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of the disease. The significance of the interplay between defect
of BBB and HD pathology still remains to be fully understood,
however, our findings support the idea that compromised BBB
seems to be strongly associated to first signs of the disease.
Recent evidence demonstrates that induction of neurovascular
breakdown at pre-symptomatic stages of the disease in an animal
model of ALS significantly accelerates motor symptoms and short-
ened mouse lifespan (20). Further studies are strongly warranted to
establish any interdependency between these two events in HD.
Our findings are supported by current evidence sustaining a
significant role for S1P signalling as a key determinant of BBB
permeability and brain homeostasis and hence as a potential
pathogenic player or therapeutic target in diseases character-
ized by both BBB dysfunction and neurodegeneration (60).
In this context, the therapeutic action of the S1PR5 stimula-
tion, by A-971432, in HD mice may represent a valuable ‘drug-
gable’ target to develop more targeted and effective therapeutic
approaches for the treatment of poorly explored aspects associ-
ated to the disease. Furthermore, the protective action that the
compound exerts on the brain neuropathology indicates that A-
971432 may serve also as a disease-modifying molecule with a
great therapeutic potential. What makes A-971432 a very attrac-
tive compound is that stimulation of S1PR5 may have more lim-
ited immune suppressive and side effects as compared with
drugs that either activate other S1P receptors (61,62) or have ad-
ditional targets, as reported for FTY720, which may antagonize
cannabinoid receptors (63), already reported to be down-regu-
lated in HD (64).
Figure 6. A-971432 prevents BBB defects when administered in R6/2 mice starting from the pre-symptomatic stage. Representative fluorescence micrographs (A) and
semi-quantitative analysis (B) of FITC-Albumin extravasation (bright green fluorescence) normalized on vessel marker laminin (red) in striatum of vehicle- and
A-971432-treated R6/2 mice at 6 weeks of age and age-matched WT controls. WT, N¼ 4; HD¼5þ 6. *, P<0.05; **, P<0.01 (one-way ANOVA with Tukey post-test). CTVF,
corrected total vessel fluorescence. Scale bar in the merge monograph represents 100 mm. Representative cropped western blottings and densitometric analysis
of Occludin (C) and Claudin-5 (D) proteins in striatal tissues from vehicle- and A-971432-treated mice at 6 weeks of age. N¼5 for each group of mice. **, P<0.01;
***, P<0.001 (one-way ANOVA with Tukey post-test).
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A possible limitation of the study is the choice of only one
animal model. However, R6/2 HD mice reflect, more than other
pre-clinical models (65,66), the BBB abnormalities characterizing
human HD pathology (17,18) and, therefore, they represent the
best model available at moment for studying such structural de-
fect and for eventually developing potential therapies.
Although our data need to be complemented by further
studies, the present findings might contribute to figure out
whether and how specific BBB drug targets can be approached
in the future.
Our work may suggest important implications for disease
pathogenesis and may help in formulating several new therapeu-
tic strategies in humans. Such strategies may be designed either
to directly target brain vascular structural abnormalities (i.e. tight
junction proteins and/or other BBB components) or to develop
sphingolipid-based approaches. In this context, A-971432 may
represent a suitable drug for future clinical testing in HD.
Collectively, our findings demonstrate a potential correlation
between BBB defects and the onset of motor deficits in HD and
provide the first evidence that brain vasculature may represent
a novel target for the development of novel therapeutic inter-
ventions for the disease.
Materials and Methods
Animal model
Breeding pairs of the R6/2 line of transgenic mice [strain name:
B6CBA-tgN (HDexon1) 62Gpb/1J] with 160610 (CAG) repeat
expansions were purchased from the Jackson Laboratories.
Male R6/2 mice were crossed with female B6CBA WT mice for
colony maintenance. All procedures on animals were approved
by the IRCCS Neuromed Animal Care Review Board and by
‘Istituto Superiore di Sanita`’ (permit number: 1163/2015-PR) and
were conducted according to EU Directive 2010/63/EU for animal
experiments.
In vivo experiments were carried out in both R6/2 mice and
WT littermates, starting from 3 or 7 weeks of age. To ensure ho-
mogeneity of experimental cohorts, mice from the same F gen-
eration were assigned to experimental groups, such that age
and weight were matched. In total, 50 female R6/2 transgenic
mice and 40 female WT littermates were used in this study. In
order to reduce the number of animals used for this study,
where possible, multiple biochemical analyses, evaluation and
record of motor function were conducted on the same group of
mice.
All animals used for biochemical and histological experi-
ments were euthanized at fixed time points. Mice used for life-
span analysis died naturally.
In-vivo drug administration
A-971432 was dissolved in DMSO, further diluted in saline (vehi-
cle) and daily administered by intraperitoneal (i.p.) injection at
dose of 0.1 mg/kg of body weight starting either at 4 of age or 7
weeks of age as described previously (23). Control mice (WT and
R6/2) were daily injected with the same volume of vehicle con-
taining DMSO.
Motor behavior tests
Motor performance was assessed by Horizontal Ladder Task
and Rotarod tests as described previously (21,67). All tests took
place during the light phase of the light–dark cycle and mice
Figure 7. Administration of A-971432 reduces mHtt aggregation in carotid arteries from R6/2 mice. Representative micrographs (A), cropped immunoblottings (B, C) and
densitometric analysis (D) of EM48-positive mHtt aggregates in carotid arteries from vehicle-treated WT mice and vehicle- and A-971432-treated R6/2 mice at 6 weeks
of age. N¼4 for each group of R6/2 mice. *, P<0.05 (unpaired t-test). Scale bar represents 100 mm. Laminin was used as loading control.
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were tested before and after the initiation of the treatment at
the indicated time points.
Brain lysate preparation
In order to clearly detect transient protein post-translation
modification, like phosphorylation, mice were sacrificed within
1 h from the last treatment by cervical dislocation and brains
were removed from the skull, weighed and bisected. Brains
were immediately snap-frozen in liquid N2 and pulverized in a
mortar with a pestle. Pulverized tissue was then homogenized
in lysis buffer containing 20 mm Tris, pH 7.4, 1% Nonidet P-40,
1 mm EDTA, 20 mm NaF, 2 mm Na3VO4 and protease inhibitor
mixture (Santa Cruz, Cat. N. sc-29131), sonicated with 2 10 s
pulses and then centrifuged for 10 min at 10 000g. Protein con-
centration was determined by Bradford method.
Immunoblottings
Proteins (40 lg) were resolved on 10% SDS-PAGE and immuno-
blotted with the following antibodies: anti-phospho-AKT (1:
1000) (Immunological Sciences Cat. N. AB-10521), anti-AKT (1:
1000) (Cell Signaling Cat. N. #2920), anti-phospho-ERK (1: 1000)
(Immunological Sciences Cat. N. AB-10762), anti-ERK (1: 1000)
(Cell Signaling, Cat. N. #4696), anti BDNF (1: 1000) (Santa Cruz,
Cat. N. sc-546), anti-Occludin (Thermo Scientific, Cat. N. 710192)
and anti-Claudin-5 (Abcam, Cat. N. ab15106). For protein nor-
malization, anti-Actin (1: 5000) (Sigma Aldrich, Cat. N. A5441)
was used. Immunoblots were then exposed to specific HRP-con-
jugated antibodies (Santa Cruz, Cat. N. sc-2004 and sc-2005).
Protein bands were visualized by ECL Plus (GE Healthcare) and
quantitated with Quantity One software (Bio-Rad Laboratories).
Analysis of striatal mHtt aggregates
WT and R6/2 mice were sacrificed by cervical dislocation. Brains
were removed and trimmed by removing the olfactory bulbs
and spinal cord. The remaining brain was processed and
embedded in paraffin wax and 10 lm coronal sections were cut
on an RM 2245 microtome (Leica Microsystems). Five mice/
group (n¼ 5) were used and four coronal sections spread
over the anterior-posterior extent of the brain (200–300 lm
inter-section distance) were scanned. For each coronal section,
a total number of 5 fields at 63 magnification were analyzed.
Immunostaining for mHtt aggregates was carried out by using
EM48 antibody (1: 200) (Millipore, Cat. N. 5374) as described pre-
viously (21). The average number of mHtt aggregate-containing
cells per brain section was quantified by ImageJ software.
For the immunoblotting analyses, cell lysate (40 lg) was re-
solved on 10% SDS-PAGE, entire gel, including the stacking por-
tion, was transblotted over-night a 250 mV in 0.05% SDS and
16% methanol-containing transfer buffer (67). Membrane was
blocked in 5% non-fat dry milk TBST for 1 h and successively
immunoblotted with EM48 and/or anti Htt Mab2166 (Millipore)
antibodies (both 1: 1000). A monoclonal anti-mouse HRP-conju-
gated antibody (Santa Cruz, Cat. N. sc-2005) was used as second-
ary antibody. Protein bands were visualized by ECL Plus (GE
Healthcare).
Evaluation of blood–brain barrier permeability
BBB integrity was evaluated using FITC-Albumin (10 mg/ml in
PBS at 10 ml/kg) (Sigma, Cat. N. A9771–100 MG) combined with
Laminin (1: 1000) (Novus Biological, Cat N. NB300–144) immu-
nostaining as described recently (18). A goat anti-rabbit CY3-
conjugate (Millipore, Cat. N. AP132) was used as secondary
antibody.
Fluorescence intensity for each single channel was analyzed
by ImageJ software. Total fluorescent signal intensity of the
FITC-albumin was normalized by the total CY3-Laminin fluores-
cent intensity per each image and reported as ‘corrected total
vessel fluorescence’ (CTVF) as described (18,68,69).
Analysis of mHtt aggregates in carotid arteries
Mouse vessels were processed and embedded in paraffin wax
and 10 lm coronal sections were cut on an RM 2245 microtome
(Leica Microsystems). Immunostaining for mHtt aggregates was
carried out by using EM48 antibody (1: 200) as reported above.
In the immunoblotting experiments, mouse carotid arteries
were snap-frozen in liquid N2 and pulverized in a mortar with a
pestle. Pulverized tissue was then homogenized in 50 ml of lysis
buffer containing 20 mm Tris, pH 7.4, 1% Nonidet P-40, 1 mm
EDTA, 20 mm NaF, 2 mm Na3VO4 and protease inhibitor mixture
(Santa Cruz, Cat. N. sc-29131), sonicated with 2 10 s pulses and
then centrifuged for 10 min at 10 000g. Total protein lysate was
then resolved on SDS-PAGE. Stacking gel portion was removed
from the separating gel and transblotted over-night a 250 mV in
0.05% SDS and 16% methanol-containing transfer buffer.
Membrane was blocked in 5% non-fat dry milk TBST for 1 h and
successively immunoblotted with EM48 antibody (1: 500) and
anti-Laminin antibody (1: 1000) (Novus Biological, Cat N. NB300–
144). HRP-conjugated monoclonal and polyclonal antibodies
(Santa Cruz, Cat. N. sc-2005 and sc-2004, respectively) were used
as secondary antibodies. Protein bands were visualized by ECL
Plus (GE Healthcare). Ponceau red staining was used as loading
control.
Statistics
Two-way ANOVA followed by Bonferroni post-test was used
to compare treatment groups with the Horizontal Ladder Task
and Rotarod tests as well as for mouse body weight analysis.
Log-rank test was used to analyze mouse survival. Two-tailed
unpaired t-test and one-way ANOVA were used in all other
experiments as indicated. All data were expressed as
mean6SD or as mean6S.E.M. as indicated.
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Supplementary Material is available at HMG online.
Acknowledgements
This work was supported by “Fondazione Neuromed” and
funded by AbbVie to VM and ADP and Italian Ministry of Health
“Ricerca Corrente” funding program to VM [Mismatch]
Conflict of Interest statement. None declared.
References
1. Walker, F.O. (2007) Huntington’s disease. Semin. Neurol., 27,
143–150.
2498 | Human Molecular Genetics, 2018, Vol. 27, No. 14
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/27/14/2490/4983968 by guest on 17 April 2020
2. Zuccato, C., Valenza, M. and Cattaneo, E. (2010) Molecular
mechanisms and potential therapeutical targets in
Huntington’s disease. Physiol. Rev., 90, 905–981.
3. Maglione, V., Cannella, M., Gradini, R., Cislaghi, G. and
Squitieri, F. (2006) Huntingtin fragmentation and increased
caspase 3, 8 and 9 activities in lymphoblasts with heterozy-
gous and homozygous Huntington’s disease mutation.
Mech. Ageing Dev., 127, 213–216.
4. Maglione, V., Cannella, M., Martino, T., De Blasi, A., Frati, L.
and Squitieri, F. (2006) The platelet maximum number of
A2A-receptor binding sites (Bmax) linearly correlates with
age at onset and CAG repeat expansion in Huntington’s dis-
ease patients with predominant chorea. Neurosci. Lett., 393,
27–30.
5. Maglione, V., Marchi, P., Di Pardo, A., Lingrell, S., Horkey, M.,
Tidmarsh, E. and Sipione, S. (2010) Impaired ganglioside me-
tabolism in Huntington’s disease and neuroprotective role
of GM1. J. Neurosci., 30, 4072–4080.
6. Di Pardo, A., Amico, E. and Maglione, V. (2016) Impaired lev-
els of gangliosides in the corpus callosum of Huntington dis-
ease animal models. Front. Neurosci., 10, 457.
7. Di Pardo, A., Amico, E., Basit, A., Armirotti, A., Joshi, P.,
Neely, D.M., Vuono, R., Castaldo, S., Digilio, A.F., Scalabri, F.
et al. (2017) Defective sphingosine-1-phosphate metabolism
is a druggable target in Huntington’s disease. Sci. Rep., 7,
5280.
8. Skene, D.J., Middleton, B., Fraser, C.K., Pennings, J.L., Kuchel,
T.R., Rudiger, S.R., Bawden, C.S. and Morton, A.J. (2017)
Metabolic profiling of presymptomatic Huntington’s disease
sheep reveals novel biomarkers. Sci. Rep., 7, 43030.
9. Moruno Manchon, J.F., Uzor, N.E., Dabaghian, Y., Furr-
Stimming, E.E., Finkbeiner, S. and Tsvetkov, A.S. (2015)
Cytoplasmic sphingosine-1-phosphate pathway modulates
neuronal autophagy. Sci. Rep., 5, 15213.
10. Pirhaji, L., Milani, P., Leidl, M., Curran, T., Avila-Pacheco, J.,
Clish, C.B., White, F.M., Saghatelian, A. and Fraenkel, E.
(2016) Revealing disease-associated pathways by network
integration of untargeted metabolomics. Nat. Methods, 13,
770–776.
11. Pirhaji, L., Milani, P., Dalin, S., Wassie, B.T., Dunn, D.E.,
Fenster, R.J., Avila-Pacheco, J., Greengard, P., Clish, C.B.,
Heiman, M. et al. (2017) Identifying therapeutic targets by
combining transcriptional data with ordinal clinical meas-
urements. Nat. Commun., 8, 623.
12. Di Pardo, A., Basit, A., Armirotti, A., Amico, E., Castaldo, S.,
Pepe, G., Marracino, F., Buttari, F., Digilio, A.F. and Maglione,
V. (2017) De novo synthesis of sphingolipids is defective in
experimental models of Huntington’s disease. Front.
Neurosci., 11, 698.
13. Dev, K.K., Mullershausen, F., Mattes, H., Kuhn, R.R., Bilbe, G.,
Hoyer, D. and Mir, A. (2008) Brain sphingosine-1-phosphate
receptors: implication for FTY720 in the treatment of multi-
ple sclerosis. Pharmacol. Ther., 117, 77–93.
14. Jaillard, C., Harrison, S., Stankoff, B., Aigrot, M.S., Calver,
A.R., Duddy, G., Walsh, F.S., Pangalos, M.N., Arimura, N.,
Kaibuchi, K. et al. (2005) Edg8/S1P5: an oligodendroglial re-
ceptor with dual function on process retraction and cell sur-
vival. J. Neurosci., 25, 1459–1469.
15. van Doorn, R., Lopes Pinheiro, M.A., Kooij, G., Lakeman, K.,
van het Hof, B., van der Pol, S.M., Geerts, D., van Horssen, J.,
van der Valk, P., van der Kam, E. et al. (2012) Sphingosine
1-phosphate receptor 5 mediates the immune quiescence of
the human brain endothelial barrier. J. Neuroinflam., 9, 133.
16. Liu, W.Y., Wang, Z.B., Zhang, L.C., Wei, X. and Li, L. (2012)
Tight junction in blood-brain barrier: an overview of struc-
ture, regulation, and regulator substances. CNS Neurosci.
Ther., 18, 609–615.
17. Drouin-Ouellet, J., Sawiak, S.J., Cisbani, G., Lagace, M., Kuan,
W.L., Saint-Pierre, M., Dury, R.J., Alata, W., St-Amour, I.,
Mason, S.L. et al. (2015) Cerebrovascular and blood-brain bar-
rier impairments in Huntington’s disease: potential implica-
tions for its pathophysiology. Ann. Neurol., 78, 160–177.
18. Di Pardo, A., Amico, E., Scalabri, F., Pepe, G., Castaldo, S.,
Elifani, F., Capocci, L., De Sanctis, C., Comerci, L., Pompeo, F.
et al. (2017) Impairment of blood-brain barrier is an early
event in R6/2 mouse model of Huntington Disease. Sci. Rep.,
7, 41316.
19. O’Sullivan, S. and Dev, K.K. (2017) Sphingosine-1-phosphate
receptor therapies: advances in clinical trials for
CNS-related diseases. Neuropharmacology, 113, 597–607.
20. Winkler, E.A., Sengillo, J.D., Sagare, A.P., Zhao, Z., Ma, Q.,
Zuniga, E., Wang, Y., Zhong, Z., Sullivan, J.S., Griffin, J.H. et al.
(2014) Blood-spinal cord barrier disruption contributes to
early motor-neuron degeneration in ALS-model mice. Proc.
Natl. Acad. Sci. U.S.A., 111, E1035–E1042.
21. Di Pardo, A., Amico, E., Favellato, M., Castrataro, R., Fucile, S.,
Squitieri, F. and Maglione, V. (2014) FTY720 (fingolimod) is a
neuroprotective and disease-modifying agent in cellular and
mouse models of Huntington disease. Hum. Mol. Genet., 23,
2251–2265.
22. Miguez, A., Garcia-Diaz Barriga, G., Brito, V., Straccia, M.,
Giralt, A., Gines, S., Canals, J.M. and Alberch, J. (2015)
Fingolimod (FTY720) enhances hippocampal synaptic plas-
ticity and memory in Huntington’s disease by preventing
p75NTR up-regulation and astrocyte-mediated inflamma-
tion. Hum. Mol. Genet., 24, 4958–4970.
23. Hobson, A.D., Harris, C.M., van der Kam, E.L., Turner, S.C.,
Abibi, A., Aguirre, A.L., Bousquet, P., Kebede, T., Konopacki,
D.B., Gintant, G. et al. (2015) Discovery of A-971432, an orally
bioavailable selective sphingosine-1-phosphate receptor 5
(s1p5) agonist for the potential treatment of neurodegenera-
tive disorders. J. Med. Chem., 58, 9154–9170.
24. van der Burg, J.M.M., Gardiner, S.L., Ludolph, A.C.,
Landwehrmeyer, G.B., Roos, R.A.C. and Aziz, N.A. (2017)
Body weight is a robust predictor of clinical progression in
Huntington disease. Ann. Neurol., 82, 479–483.
25. DeLeo, M.J., 3rd, Gounis, M.J., Hong, B., Ford, J.C., Wakhloo,
A.K. and Bogdanov, A.A. Jr. (2009) Carotid artery brain aneu-
rysm model: in vivo molecular enzyme-specific MR imaging
of active inflammation in a pilot study. Radiology, 252,
696–703.
26. Moruno-Manchon, J.F., Uzor, N.E., Blasco-Conesa, M.P.,
Mannuru, S., Putluri, N., Furr-Stimming, E.E. and Tsvetkov,
A.S. (2017) Inhibiting sphingosine kinase 2 mitigates mutant
Huntingtin-induced neurodegeneration in neuron models of
Huntington disease. Hum. Mol. Genet., 26, 1305–1317.
27. Chang, R., Liu, X., Li, S. and Li, X.J. (2015) Transgenic animal
models for study of the pathogenesis of Huntington’s dis-
ease and therapy. Drug Des. Devel. Ther., 9, 2179–2188.
28. Neueder, A., Landles, C., Ghosh, R., Howland, D., Myers, R.H.,
Faull, R.L.M., Tabrizi, S.J. and Bates, G.P. (2017) The patho-
genic exon 1 HTT protein is produced by incomplete splicing
in Huntington’s disease patients. Sci. Rep., 7, 1307.
29. Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper,
A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H.,
Davies, S.W. et al. (1996) Exon 1 of the HD gene with an
2499Human Molecular Genetics, 2018, Vol. 27, No. 14 |
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/27/14/2490/4983968 by guest on 17 April 2020
expanded CAG repeat is sufficient to cause a progressive
neurological phenotype in transgenic mice. Cell, 87, 493–506.
30. Davies, S.W. and Scherzinger, E. (1997) Nuclear inclusions in
Huntington’s disease. Trends Cell Biol., 7, 422.
31. Carter, R.J., Lione, L.A., Humby, T., Mangiarini, L., Mahal, A.,
Bates, G.P., Dunnett, S.B. and Morton, A.J. (1999)
Characterization of progressive motor deficits in mice trans-
genic for the human Huntington’s disease mutation.
J. Neurosci., 19, 3248–3257.
32. Vonsattel, J.P. (2007) Huntington disease models and
human neuropathology: similarities and differences. Acta
Neuropathol., 115, 55–69.
33. Brinkmann, V. (2007) Sphingosine 1-phosphate receptors in
health and disease: mechanistic insights from gene deletion
studies and reverse pharmacology. Pharmacol. Ther., 115,
84–105.
34. Apostol, B.L., Illes, K., Pallos, J., Bodai, L., Wu, J., Strand, A.,
Schweitzer, E.S., Olson, J.M., Kazantsev, A., Marsh, J.L. et al.
(2006) Mutant huntingtin alters MAPK signaling pathways in
PC12 and striatal cells: ERK1/2 protects against mutant
huntingtin-associated toxicity. Hum. Mol. Genet., 15, 273–285.
35. Colin, E., Regulier, E., Perrin, V., Durr, A., Brice, A., Aebischer,
P., Deglon, N., Humbert, S. and Saudou, F. (2005) Akt is al-
tered in an animal model of Huntington’s disease and in
patients. Eur. J. Neurosci., 21, 1478–1488.
36. Varma, H., Yamamoto, A., Sarantos, M.R., Hughes, R.E. and
Stockwell, B.R. (2010) Mutant huntingtin alters cell fate
in response to microtubule depolymerization via the
GEF-H1-RhoA-ERK pathway. J. Biol. Chem., 285, 37445–37457.
37. Humbert, S., Bryson, E.A., Cordelieres, F.P., Connors, N.C.,
Datta, S.R., Finkbeiner, S., Greenberg, M.E. and Saudou, F.
(2002) The IGF-1/Akt pathway is neuroprotective in
Huntington’s disease and involves Huntingtin phosphoryla-
tion by Akt. Dev. Cell, 2, 831–837.
38. Bodai, L. and Marsh, J.L. (2012) A novel target for
Huntington’s disease: eRK at the crossroads of signaling.
The ERK signaling pathway is implicated in Huntington’s
disease and its upregulation ameliorates pathology.
Bioessays, 34, 142–148.
39. Sarantos, M.R., Papanikolaou, T., Ellerby, L.M. and Hughes,
R.E. (2012) Pizotifen activates ERK and provides neuroprotec-
tion in vitro and in vivo in models of Huntington’s disease.
J. Huntingtons Dis., 1, 195–210.
40. Budni, J., Bellettini-Santos, T., Mina, F., Garcez, M.L. and
Zugno, A.I. (2015) The involvement of BDNF, NGF and GDNF
in aging and Alzheimer’s disease. Aging Dis., 6, 331–341.
41. Bathina, S. and Das, U.N. (2015) Brain-derived neurotrophic
factor and its clinical implications. Arch. Med. Sci., 11,
1164–1178.
42. Zuccato, C. and Cattaneo, E. (2009) Brain-derived neurotro-
phic factor in neurodegenerative diseases. Nat. Rev. Neurol.,
5, 311–322.
43. Binder, D.K. and Scharfman, H.E. (2004) Brain-derived neuro-
trophic factor. Growth Factors, 22, 123–131.
44. Giampa, C., Montagna, E., Dato, C., Melone, M.A., Bernardi, G.
and Fusco, F.R. (2013) Systemic delivery of recombinant
brain derived neurotrophic factor (BDNF) in the R6/2 mouse
model of Huntington’s disease. PLoS One, 8, e64037.
45. Giralt, A., Carreton, O., Lao-Peregrin, C., Martin, E.D. and
Alberch, J. (2011) Conditional BDNF release under pathologi-
cal conditions improves Huntington’s disease pathology by
delaying neuronal dysfunction. Mol. Neurodegener., 6, 71.
46. Deogracias, R., Yazdani, M., Dekkers, M.P., Guy, J., Ionescu,
M.C., Vogt, K.E. and Barde, Y.A. (2012) Fingolimod, a
sphingosine-1 phosphate receptor modulator, increases
BDNF levels and improves symptoms of a mouse model of
Rett syndrome. Proc. Natl. Acad. Sci. U.S.A., 109, 14230–14235.
47. Ren, M., Han, M., Wei, X., Guo, Y., Shi, H., Zhang, X., Perez,
R.G. and Lou, H. (2017) FTY720 attenuates
6-OHDA-associated dopaminergic degeneration in cellular
and mouse Parkinsonian models. Neurochem. Res., 42,
686–696.
48. Qiao, L.Y., Yu, S.J., Kay, J.C. and Xia, C.M. (2013) In vivo regu-
lation of brain-derived neurotrophic factor in dorsal root
ganglia is mediated by nerve growth factor-triggered Akt ac-
tivation during cystitis. PLoS One, 8, e81547.
49. Hisaoka-Nakashima, K., Kajitani, N., Kaneko, M., Shigetou,
T., Kasai, M., Matsumoto, C., Yokoe, T., Azuma, H.,
Takebayashi, M., Morioka, N. et al. (2016) Amitriptyline indu-
ces brain-derived neurotrophic factor (BDNF) mRNA expres-
sion through ERK-dependent modulation of multiple BDNF
mRNA variants in primary cultured rat cortical astrocytes
and microglia. Brain Res., 1634, 57–67.
50. Johnson-Farley, N.N., Patel, K., Kim, D. and Cowen, D.S.
(2007) Interaction of FGF-2 with IGF-1 and BDNF in stimulat-
ing Akt, ERK, and neuronal survival in hippocampal cultures.
Brain Res., 1154, 40–49.
51. Arrasate, M., Mitra, S., Schweitzer, E.S., Segal, M.R. and
Finkbeiner, S. (2004) Inclusion body formation reduces levels
of mutant huntingtin and the risk of neuronal death. Nature,
431, 805–810.
52. Sanchez, I., Mahlke, C. and Yuan, J. (2003) Pivotal role of olig-
omerization in expanded polyglutamine neurodegenerative
disorders. Nature, 421, 373–379.
53. Feldman, G.J., Mullin, J.M. and Ryan, M.P. (2005) Occludin:
structure, function and regulation. Adv. Drug Deliv. Rev., 57,
883–917.
54. Piontek, J., Winkler, L., Wolburg, H., Muller, S.L., Zuleger, N.,
Piehl, C., Wiesner, B., Krause, G. and Blasig, I.E. (2008)
Formation of tight junction: determinants of homophilic in-
teraction between classic claudins. Faseb J., 22, 146–158.
55. Honda, M., Nakagawa, S., Hayashi, K., Kitagawa, N.,
Tsutsumi, K., Nagata, I. and Niwa, M. (2006) Adrenomedullin
improves the blood-brain barrier function through the ex-
pression of claudin-5. Cell Mol. Neurobiol., 26, 109–118.
56. McCarthy, K.M., Skare, I.B., Stankewich, M.C., Furuse, M.,
Tsukita, S., Rogers, R.A., Lynch, R.D. and Schneeberger, E.E.
(1996) Occludin is a functional component of the tight junc-
tion. J. Cell Sci., 109 (Pt 9), 2287–2298.
57. Yu, Y.B., Zhao, D.Y., Qi, Q.Q., Long, X., Li, X., Chen, F.X. and
Zuo, X.L. (2017) BDNF modulates intestinal barrier integrity
through regulating the expression of tight junction proteins.
Neurogastroenterol. Motil., 29, e12967.
58. Zhao, D.Y., Zhang, W.X., Qi, Q.Q., Long, X., Li, X., Yu, Y.B. and
Zuo, X.L. (2018) Brain-derived neurotrophic factor modulates
intestinal barrier by inhibiting intestinal epithelial cells apo-
ptosis in mice. Physiol. Res., in press.
59. Li, Y., Lucas-Osma, A.M., Black, S., Bandet, M.V., Stephens,
M.J., Vavrek, R., Sanelli, L., Fenrich, K.K., Di Narzo, A.F.,
Dracheva, S. et al. (2017) Pericytes impair capillary blood flow
and motor function after chronic spinal cord injury. Nat.
Med., 23, 733–741.
60. Prager, B., Spampinato, S.F. and Ransohoff, R.M. (2015)
Sphingosine 1-phosphate signaling at the blood-brain bar-
rier. Trends Mol. Med., 21, 354–363.
61. Park, S.J. and Im, D.S. (2017) Sphingosine 1-phosphate recep-
tor modulators and drug discovery. Biomol. Ther., 25, 80–90.
2500 | Human Molecular Genetics, 2018, Vol. 27, No. 14
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/27/14/2490/4983968 by guest on 17 April 2020
62. Gonzalez-Cabrera, P.J., Brown, S., Studer, S.M. and Rosen, H.
(2014) S1P signaling: new therapies and opportunities.
F1000Prime Rep., 6, 109.
63. Paugh, S.W., Cassidy, M.P., He, H., Milstien, S., Sim-Selley,
L.J., Spiegel, S. and Selley, D.E. (2006) Sphingosine and its an-
alog, the immunosuppressant 2-amino-2-(2-[4-octylpheny-
l]ethyl)-1, 3-propanediol, interact with the CB1 cannabinoid
receptor. Mol. Pharmacol., 70, 41–50.
64. Basavarajappa, B.S., Shivakumar, M., Joshi, V. and
Subbanna, S. (2017) Endocannabinoid system in neurode-
generative disorders. J. Neurochem., 142, 624–648.
65. Mantovani, S., Gordon, R., Li, R., Christie, D.C., Kumar, V. and
Woodruff, T.M. (2016) Motor deficits associated with
Huntington’s disease occur in the absence of striatal degenera-
tion in BACHD transgenic mice.Hum.Mol. Genet., 25, 1780–1791.
66. Franciosi, S., Ryu, J.K., Shim, Y., Hill, A., Connolly, C.,
Hayden, M.R., McLarnon, J.G. and Leavitt, B.R. (2012)
Age-dependent neurovascular abnormalities and altered
microglial morphology in the YAC128 mouse model of
Huntington disease. Neurobiol. Dis., 45, 438–449.
67. Di Pardo, A., Maglione, V., Alpaugh, M., Horkey, M., Atwal,
R.S., Sassone, J., Ciammola, A., Steffan, J.S., Fouad, K.,
Truant, R. et al. (2012) Ganglioside GM1 induces
phosphorylation of mutant huntingtin and restores
normal motor behavior in Huntington disease mice.
Proc. Natl. Acad. Sci. U.S.A., 109, 3528–3533.
68. McCloy, R.A., Rogers, S., Caldon, C.E., Lorca, T., Castro, A. and
Burgess, A. (2014) Partial inhibition of Cdk1 in G 2 phase
overrides the SAC and decouples mitotic events. Cell Cycle,
13, 1400–1412.
69. Burgess, A., Vigneron, S., Brioudes, E., Labbe, J.C., Lorca, T.
and Castro, A. (2010) Loss of human Greatwall results in G2
arrest and multiple mitotic defects due to deregulation of
the cyclin B-Cdc2/PP2A balance. Proc. Natl. Acad. Sci. U.S.A.,
107, 12564–12569.
2501Human Molecular Genetics, 2018, Vol. 27, No. 14 |
D
ow
nloaded from
 https://academ
ic.oup.com
/hm
g/article-abstract/27/14/2490/4983968 by guest on 17 April 2020
